• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Blackford Gary bought $659,300 worth of shares (60,000 units at $10.99), increasing direct ownership by 28% to 91,593 units (SEC Form 4)

    8/15/25 12:02:50 PM ET
    $AVNS
    Industrial Specialties
    Health Care
    Get the next $AVNS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BLACKFORD GARY

    (Last) (First) (Middle)
    5405 WINDWARD PARKWAY

    (Street)
    ALPHARETTA GA 30004

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AVANOS MEDICAL, INC. [ AVNS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/13/2025 P 20,000 A $10.975(1) 91,593 D
    Common Stock 08/13/2025 P 40,000 A $10.995(2) 40,000 I Shares held in trust.(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.94 to $11.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.98 to $11.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    3. These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
    Remarks:
    /s/ Mojirade James, as attorney-in-fact for Gary D. Blackford 08/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVNS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVNS

    DatePrice TargetRatingAnalyst
    7/25/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    5/22/2023$31.00Buy
    CL King
    2/24/2022$47.00 → $41.00Overweight
    Keybanc
    1/7/2022$37.00 → $36.00Underweight
    Morgan Stanley
    8/4/2021$45.00 → $41.00Underweight
    Morgan Stanley
    8/4/2021$60.00 → $45.00Overweight → Equal-Weight
    Stephens
    8/4/2021$55.00 → $47.00Overweight
    Keybanc
    More analyst ratings

    $AVNS
    SEC Filings

    View All

    SEC Form 10-Q filed by Avanos Medical Inc.

    10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)

    8/5/25 4:10:21 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

    8/5/25 6:49:38 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avanos Medical Inc.

    SCHEDULE 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

    7/29/25 11:24:56 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A

    8/5/25 6:45:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. Announces Second Quarter 2025 Results

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2025 financial results. "Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was solid, and the steady progress we've made against each of our transfor

    8/5/25 6:30:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical

    ALPHARETTA, Ga., July 31, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), announced today the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC. This transaction aligns with Avanos' ongoing transformation, which is focused on advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems. The divested portfolio includes the TriVisc® and GenVisc® 850 injection products, which are indicated for the treatment of osteoarthritis (OA) pain in the knee. These

    7/31/25 4:15:00 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blackford Gary bought $659,300 worth of shares (60,000 units at $10.99), increasing direct ownership by 28% to 91,593 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    8/15/25 12:02:50 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    Former Interim CEO Greiner Michael covered exercise/tax liability with 24,245 shares, decreasing direct ownership by 11% to 200,019 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    5/14/25 2:28:49 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    New insider Pickett Jason Marc claimed ownership of 40,113 shares (SEC Form 3)

    3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    4/29/25 3:45:04 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avanos Medical downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

    7/25/23 6:15:12 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    CL King initiated coverage on Avanos Medical with a new price target

    CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

    5/22/23 8:52:10 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Keybanc reiterated coverage on Avanos Medical with a new price target

    Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

    2/24/22 4:48:01 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blackford Gary bought $659,300 worth of shares (60,000 units at $10.99), increasing direct ownership by 28% to 91,593 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    8/15/25 12:02:50 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    3/11/24 5:15:37 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Leadership Updates

    Live Leadership Updates

    View All

    Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A

    8/5/25 6:45:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. Welcomes Camille Chang Gilmore as Senior Vice President and Chief Human Resources Officer

    ALPHARETTA, Ga., June 9, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a leading medical technology company focused on delivered innovative healthcare solutions, today announced the appointment of Camille Chang Gilmore as senior vice president and chief human resources officer. In this role, Gilmore will lead all aspects of Avanos' people strategy, including talent acquisition and development, workforce planning, leadership development and employee experience. Her arrival reflects the company's continued commitment to building a workplace where every employee feels val

    6/9/25 7:15:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

    ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

    3/17/25 7:30:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Financials

    Live finance-specific insights

    View All

    Avanos Medical, Inc. Announces Second Quarter 2025 Results

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2025 financial results. "Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was solid, and the steady progress we've made against each of our transfor

    8/5/25 6:30:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. Announces First Quarter 2025 Results

    ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

    5/6/25 7:00:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

    ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

    4/28/25 7:47:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avanos Medical Inc.

    SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

    11/14/24 1:28:34 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

    SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

    2/14/24 11:41:02 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

    SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

    2/13/24 4:58:57 PM ET
    $AVNS
    Industrial Specialties
    Health Care